4.7 Article

Comparison of the Vidas C-difficile GDH Automated Enzyme-Linked Fluorescence Immunoassay (ELFA) with Another Commercial Enzyme Immunoassay (EIA) (Quik Chek-60), Two Selective Media, and a PCR Assay for gluD for Detection of Clostridium difficile in Fecal Samples

Journal

JOURNAL OF CLINICAL MICROBIOLOGY
Volume 53, Issue 6, Pages 1931-1934

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.00649-15

Keywords

-

Categories

Funding

  1. bioMerieux (France)
  2. Actelion
  3. Cubist
  4. Astellas
  5. Merck
  6. Optimer
  7. Sanofi Pasteur
  8. AstraZeneca
  9. Durata
  10. Nabriva
  11. Novacta
  12. Pfizer
  13. Roche
  14. Basilea
  15. The Medicines Company
  16. VH Squared
  17. Cerexa
  18. Abbott
  19. bioMerieux
  20. Da Volterra
  21. European Tissue Symposium

Ask authors/readers for more resources

Prevention and management of Clostridium difficile infection (CDI) can be improved by rapid and reliable diagnostics. The Vidas C. difficile glutamate dehydrogenase assay had performance comparable to that of the Quik Chek-60 assay (overall agreement, 95%) and a sensitivity of >93%; thus, it is suitable as the first test in two-stage algorithms for a CDI diagnosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available